[HTML][HTML] Dupilumab: an emerging therapy in allergic fungal rhinosinusitis

AA Bulkhi, AA Mirza, AJ Aburiziza… - World Allergy Organization …, 2022 - Elsevier
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat.
Patients with recurrent attacks of the disease despite surgical management can benefit from …

Dupilumab: An emerging therapy in allergic fungal rhinosinusitis

AA Bulkhi, AA Mirza, AJ Aburiziza… - The World Allergy …, 2022 - pubmed.ncbi.nlm.nih.gov
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat.
Patients with recurrent attacks of the disease despite surgical management can benefit from …

[HTML][HTML] Dupilumab: An emerging therapy in allergic fungal rhinosinusitis

AA Bulkhi, AA Mirza, AJ Aburiziza… - The World Allergy …, 2022 - ncbi.nlm.nih.gov
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat.
Patients with recurrent attacks of the disease despite surgical management can benefit from …

[HTML][HTML] Dupilumab: An emerging therapy in allergic fungal rhinosinusitis

AA Bulkhi, AA Mirza… - World Allergy …, 2022 - worldallergyorganizationjournal.org
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat.
Patients with recurrent attacks of the disease despite surgical management can benefit from …

Dupilumab: An emerging therapy in allergic fungal rhinosinusitis.

AA Bulkhi, AA Mirza, AJ Aburiziza… - The World Allergy …, 2022 - europepmc.org
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat.
Patients with recurrent attacks of the disease despite surgical management can benefit from …